Author:
Zhang Weidong,Huang Bo,Wang Jing,Menon Sandeep
Reference63 articles.
1. Albert, S. R., Sinicrope, F. A., & Grothey, A. (2005). N0147: A randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clinical Colorectal Cancer, 5(3), 211–213.
2. Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D., et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(10), 1626–1634.
3. Baker, S. G., & Freedman, L. S. (1995). Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. Journal of the National Cancer Institute, 87, 1137–1144.
4. Baker, S. G., & Kramer, B. S. (2005). Statistics for weighing benefits and harms in a proposed genetic substudy of a randomized cancer prevention trial. Applied Statistics, 54(5), 941–954.
5. Baker, S. G., Kramer, B. S., Sargent, D. J., & Bonetti, M. (2012). Biomarkers, subgroup evaluation, and clinical trial design. Discovery medicine, 13(70), 187–192.